Date: 2026-04-06 Quarter: Q4 FY26 (ended January 31, 2026; reported March 3, 2026) Price: $22.59 | Market Cap: $3.84B | EV: $2.58B | Cash: $1.26B (zero debt)
Growth deceleration into mid-teens is real and the market is pricing it accurately. Q4 itself was a clean beat — $260.4M revenue (+3.5% vs guide), 20.5% non-GAAP op margin, record $1M+ customer adds. But the FY27 guide of 15-17% growth with 500 bps of margin compression is the thesis-defining data point. At 2.5x EV/run-rate revenue with $1.26B cash and zero debt, the downside is limited — but limited downside is not a thesis. I need to see NRR stabilise, go-to-market ramp deliver bookings growth, and concrete DAP metrics before this becomes actionable.
Classification: WATCH. Not a buy, not a sell (because I don't own it). Interesting valuation, but growth trajectory and new management execution are unproven.
This is the view that matters. Compare each quarter's QoQ to the same quarter in all prior years.
| Quarter | FY23 QoQ | FY24 QoQ | FY25 QoQ | FY26 QoQ | Trend |
|---|---|---|---|---|---|
| Q1 | — | +3.3% | +3.3% | +1.5% | Decelerating |
| Q2 | +15.6% | +10.0% | +7.9% | +10.0% | Rebounded (noise?) |
| Q3 | +11.9% | +7.2% | +7.3% | +3.6% | Decelerating |
| Q4 | +8.8% | +9.4% | +7.9% | +6.5% | Decelerating |
Three of four quarters show clear year-over-year QoQ deceleration in FY26. Q2 is the exception — the +10.0% QoQ rebound in FY26 matched FY24 but this looks more like timing than trend. The underlying trajectory is unmistakable: slowing.
| Quarter | FY24 YoY | FY25 YoY | FY26 YoY | Trend |
|---|---|---|---|---|
| Q1 | +45.2% | +33.3% | +26.8% | Decelerating |
| Q2 | +38.2% | +30.8% | +29.2% | Stable/slight decel |
| Q3 | +32.5% | +30.9% | +24.7% | Decelerating |
| Q4 | +33.3% | +29.1% | +23.2% | Decelerating |
| Full Year | +36.7% | +30.9% | +25.8% | Decelerating |
This is not 2 quarters of deceleration — it's 3 years of it. FY24 was ~37% growth, FY25 ~31%, FY26 ~26%, FY27 guided 16%. That's a roughly 6-7pp annual step-down. Predictable, yes. But predictable deceleration is still deceleration.
| Quarter | FY23 | FY24 | FY25 | FY26 | Trend |
|---|---|---|---|---|---|
| Q1 | — | +$4.0 | +$5.4 | +$3.1 | Weak |
| Q2 | +$13.6 | +$12.7 | +$13.4 | +$21.5 | Strong |
| Q3 | +$12.0 | +$10.1 | +$13.4 | +$8.4 | Weak |
| Q4 | +$9.9 | +$14.1 | +$15.4 | +$16.0 | Steady growth |
| Full Year | +$35.5 | +$40.9 | +$47.6 | +$49.0 | Steady but slowing |
FY26 added $49.0M sequentially vs FY25's 47.6M—growthinabsolutedollaraddsisbarelyexpanding.Atthisrevenuebase( 1B), you need to add more dollars just to maintain the same growth rate. This is law-of-large-numbers math, and it's not being overcome.
| Metric | Q4 FY25 | Q4 FY26 | Delta | FY26 | FY27 Guide |
|---|---|---|---|---|---|
| GAAP GM | 89.2% | 86.6% | -2.6pp | 87% | — |
| Non-GAAP GM | 91.0% | 89.0% | -2.0pp | 89% | 85-87% |
| GAAP Op Margin | -9.1% | -2.0% | +7.1pp | -7% | — |
| Non-GAAP Op Margin | 17.7% | 20.5% | +2.8pp | 17% | 12-13% |
| FCF Margin (Q4) | 29.4% | 16.1% | -13.3pp | 23% | — |
| SBC as % Rev | 22.0% | 20.4% | -1.6pp | 22.5% | — |
The Q4 results are mixed on margins. Non-GAAP operating margin expanded nicely (+2.8pp YoY to 20.5%), but gross margin is in a clear downtrend (90.2% → 89.2% → 86.6% on GAAP over 3 years). The FY27 guide of 85-87% non-GAAP GM confirms this is structural — SaaS/Dedicated/DAP mix shift, not a blip.
The FCF margin drop concerns me. Q4 FY26 FCF of $41.8M (16.1% margin) vs $62.1M (29.4%) a year ago. FY26 total FCF was $219.6M (23% margin), which is excellent, but the Q4 decline is notable. Need to watch this.
SBC remains elevated at 22.5% of FY26 revenue ($215M). Basic shares grew +3.8% YoY (163.1M → 169.3M). That's within my <5% threshold but still dilutive. The $400M buyback authorisation is a partial offset — at $22.59 that's ~17.7M shares or ~10% of outstanding.
| Q4 FY25 | Q4 FY26 | FY26 | FY27 Guide | |
|---|---|---|---|---|
| GAAP EPS | $0.04 | -$0.02 | -$0.34 | — |
| Non-GAAP EPS | $0.33 | $0.30 | $0.96 | 0.76−0.80 |
| Non-GAAP Diluted Shares (M) | 170.1 | 172.1 | 171.6 | ~175 |
Non-GAAP EPS actually declined YoY ($0.33 → $0.30) despite op margin expansion — driven by higher tax rate (22% fixed rate post-IP relocation) and higher share count. The FY27 guide of 0.76−0.80 vs Street consensus of ~$1.05 was the catalyst for the -9.85% AH sell-off.
| Quarter | Q4 FY25 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|
| cRPO ($m) | 579.2 | 621.6 | 659.1 | 719.4 |
| cRPO YoY | — | — | ~+22% | +24.2% |
| Revenue YoY | 29.1% | 29.2% | 24.7% | 23.2% |
cRPO growth (+24.2%) exceeding revenue growth (+23.2%) is a mild bullish divergence. This tells me near-term bookings are healthy. But the gap is small — only 1pp. Contrast this with AXON in July 2023 where RPO was growing at 61% vs revenue at 34% — a 27pp gap. That was a screaming signal. This is a whisper.
| Quarter | Q4 FY25 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|
| NRR | 123% | 121% | 119% | 118% |
I told you so. In April 2024, I decomposed GTLB's NRR and showed that ex-pricing increases, organic NRR was already flat at ~118%. That analysis showed that pricing impact was responsible for 29-40% of the expansion above 100% in FY24. The pricing tailwinds have now fully faded, and we're left with the organic expansion rate — which is exactly 118%.
CFO Ross guided NRR to "trend down slightly before stabilizing." I expect 115-116% as the trough. At 115%, that's still healthy — but it means existing customers are expanding at only 15% per year. That constrains overall revenue growth mathematically: you need significant new logo acquisition to compensate.
Gross retention at >90% (4-year best) is the silver lining. The problem isn't churn — it's expansion. The price-sensitive cohort (~20% of ARR) isn't expanding, and that's a drag.
| Metric | Q4 FY25 | Q4 FY26 | YoY |
|---|---|---|---|
| $1M+ Customers | 123 | 155 | +26% |
| $100K+ Customers | 1,229 | 1,456 | +18% |
| $5K+ Customers | ~9,900 | 10,682 | +8% |
Record $1M+ customer adds in Q4 is genuinely impressive. The $1M+ cohort growing at 26% — faster than revenue — tells me enterprise appetite for the platform is real. These are $1M+ annual contracts from large enterprises. This is the leading indicator I'd weight most heavily for GTLB's long-term trajectory.
But note the bifurcation: $5K+ only growing 8%. The small customer base is barely expanding. This matches the NRR story — enterprise healthy, mid-market/SMB struggling.
The leading indicators tell a split story:
This is not the kind of leading indicator divergence that gets me excited. For that, I need 2+ indicators clearly accelerating while revenue is stable. Here I have mixed signals, which matches the "transition year" narrative perfectly.
New CFO Jessica Ross delivered a transparent, well-structured guidance walk-down. She broke the 26% to 16% deceleration into four discrete factors (non-recurring tailwinds, ratable math, go-to-market ramp lag, segment caution). She ran an investor listening campaign and provided more guidance build-up detail than prior CFOs. This is the right approach for a new CFO inheriting a deceleration story. I give her credit for transparency.
CEO Bill Staples was strategic and ambitious — "generational company" language, agentic AI positioning, five growth initiatives. The substance around DAP (hybrid pricing, included credits, usage signals) is thoughtful. But I note: he's been CEO for ~14 months and growth has decelerated from 33% to 23% on his watch. The go-to-market rebuild should have started sooner.
C-suite turnover is a concern. CEO (Dec 2024), CFO (Jan 2026), CPO/CMO, CIO — all turned over within 12 months. Atlas's scuttlebutt flagged Glassdoor 3.7/5 and Blind reviews describing cultural degradation since the founder departed. For a developer tool company, engineering culture retention is existential. I weight this risk more heavily than Atlas does.
The founder left. Sid Sijbrandij was GTLB. GTLB under Sid was a company I understood — transparent handbook, rapid iteration, clear vision. GTLB under Staples is a company I'm still evaluating. My framework strongly prefers founder-led companies, and this is no longer one.
| Metric | Value | Assessment |
|---|---|---|
| EV/Run-Rate Revenue | 2.48x | Very cheap for 89% GM SaaS |
| EV/FY27 Revenue (NTM) | 2.33x | Cheap |
| P/S (market cap) | 3.69x | Cheap |
| Non-GAAP P/E (run-rate, Q4 x 4) | 18.8x | Cheap |
| Non-GAAP P/E (FY27 guide mid) | 29.0x | Fair |
| Cash as % of Market Cap | 32.8% | Fortress |
| Rule of 40 (FY26: growth + FCF margin) | 49.0 | Healthy |
| Rule of 40 (Q4: 23.2% + 16.1%) | 39.3 | Acceptable |
The valuation is objectively cheap. 2.5x EV/S for an 89% gross margin, FCF-positive SaaS company approaching $1B ARR. Cash is a third of market cap. No debt. Authorized $400M buyback (10.4% of market cap). The market is pricing this as if growth falls below 10% permanently.
But cheap is not a catalyst. Companies can stay cheap for years if growth keeps decelerating. SNOW taught us that. The question isn't whether GTLB is cheap — it clearly is — but whether there's a catalyst to re-rate. I see three potential catalysts:
All three are 6-12 months away. No near-term catalyst.
September 2022 (Q2 FY23 earnings): I was positive. NRR was ~152%, no macro impact, record hyperscaler contribution, 61% YoY customer growth. I noted the CTO resignation as a concern. I held GTLB at ~4.2% allocation.
April 2024 (NRR decomposition): I did deep work decomposing NRR and showed that ex-pricing, organic NRR was flat at ~118%. That analysis showed that pricing impact was responsible for 29-40% of the expansion above 100% in FY24. The pricing tailwinds have now fully faded, and we're left with the organic expansion rate — which is exactly 118%.
Today: The company that had 152% NRR and 38%+ growth in 2022-2023 is now a 23% grower with 118% NRR guided to decline further. The growth profile is fundamentally different. This is no longer a hypergrowth company; it's transitioning to durable mid-teens growth with profitability and FCF. That's a fine business — but it's not the business I invested in.
Atlas scored this 2.5/5 conviction. I'd push it to 2/5 for the following reasons:
Management risk is under-weighted. Complete C-suite turnover within 12 months, negative Glassdoor/Blind reviews, and this is no longer founder-led. For a developer platform, culture is the product. Atlas notes this but doesn't dock it enough.
The "transition year" excuse. Eish!! How many times have we heard "transition year" from new management? Sometimes it's genuine (AXON under Rick Smith during body cam rollout). Often it's a euphemism for "we don't know how to grow this faster." I need proof.
NRR decline was predictable — my own work showed it. Atlas treats this as new information. It's not. The pricing tailwind fade was visible 2 years ago. What IS new is the CFO guiding further decline before stabilisation. That's incrementally negative.
Where I agree with Atlas: valuation is cheap, cRPO mildly bullish, $1M+ customer adds impressive, DAP optionality real. The balance sheet is a fortress.
Thesis: WATCH — Not Actionable Yet
GitLab is a high-quality platform company (89% gross margin, $1B ARR, zero debt, $1.26B cash) that is decelerating from hypergrowth to durable mid-teens growth under a new, unproven management team. The valuation (~2.5x EV/S) prices in a lot of the bad news. DAP is a legitimate agentic AI play with smart monetisation design. But growth trajectory, NRR decline, margin compression, and management execution are all working against the stock near-term.
I would get interested if:
I would run for the hills if:
Next earnings to watch: Q1 FY27 (June 8, 2026). Guide is 253 − 255M.Iftheybeatby3261M+), it confirms the guide is sandbagged and the go-to-market ramp is working. If they guide Q2 with deceleration below 17% YoY, the thesis weakens further.
-wsm
(No position in GTLB)